CTOs on the Move

Arcturus Therapeutics

www.arcturusrx.com

 
Arcturus Therapeutics is a preclinical drug delivery and nucleic acid medicines company. We are focused on developing novel technologies to build the next generation of safe, effective RNA and DNA medicines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and nucleic acid-based therapeutics. Arcturus Therapeutics is presently recruiting outstanding candidates with experience in the field of RNA technologies and nanoparticle sciences. Only exceptional applicants need apply. Compensation and equity position is commensurate.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.arcturusrx.com
  • 10628 Science Center Drive Suite 250
    San Diego, CA USA 92121
  • Phone: 858.900.2660

Executives

Name Title Contact Details

Similar Companies

Lung Therapeutics

Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions.

Broncus Technologies, Inc.

Broncus Medical, Inc. is a well-funded, commercial stage company based in San Jose, CA. The Company`s mission is to deliver navigation, diagnostic & therapeutic technologies to treat patients with lung disease. The Company has a comprehensive intellectual property portfolio with over 75 patents including those issued, licensed, and pending. Along with Broncus Medical`s focus on technological advancements, it is committed to providing outstanding value to patients, healthcare professionals, investors and employees.

IDx Technologies

IDx is a leading AI diagnostics company on a mission to transform the quality, accessibility, and affordability of healthcare.

Athenix

Athenix Corp. is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Renovacor

Renovacor is a preclinical gene therapy company developing a pipeline of innovative and proprietary AAV based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Renovacor`s therapeutic focus is initially on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.